Back to search
FDAFDA · Food and drugs·Recall number D-0313-2015

Dacarbazine, Injection, USP, 200mg, vials packaged in individual cartons, Rx only, Manufactured by Hospira Australia 1 Lexia Place, Mulgrave, Victoria Australia 3170. NDC 61703-327-22.

Published December 31, 2014 · Recall initiated: November 25, 2014

Summary

FDA records drug Class III recall D-0313-2015, published December 31, 2014 and initiated November 25, 2014. Recalling firm: Hospira Inc.; Status: Terminated; Reported quantity: 3,306 vials; Lot: Lot #: B032223AA; Exp: July 2016. Class III means the product is not likely to cause adverse health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Discoloration: Reconstituted solution may appear pink instead of colorless to pale yellow when stored per the labeled conditions.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Hospira Inc.
Distributor
Nationwide
Lot
Lot #: B032223AA; Exp: July 2016
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Dacarbazine, Injection, USP, 200mg, vials packaged in individual cartons, Rx only, Manufactured by Hospira Australia 1 Lexia Place, Mulgrave, Victoria Australia 3170. NDC 61703-327-22. recalled?

Yes. FDA published recall D-0313-2015 on December 31, 2014. Reported hazard: Discoloration: Reconstituted solution may appear pink instead of colorless to pale yellow when stored per the labeled conditions.

What should I do if I have this product?

Voluntary: Firm initiated · Letter